You could be reading the full-text of this article now if you...

If you have access to this article through your institution,
you can view this article in

Treatment of Fungal Keratitis From Fusarium Infection by Corneal Cross-Linking

Galperin, Gustavo MD*†; Berra, Martín MD*†; Tau, Julia MS*; Boscaro, Gabriela MS‡; Zarate, Jorge PhD*; Berra, Alejandro PhD*

Cornea:
doi: 10.1097/ICO.0b013e318221cec7
Basic Investigation
Abstract

Purpose: To evaluate the efficacy of corneal cross-linking (CXL) (riboflavin–UV-A) as a simple therapy in Fusarium keratitis.

Methods: Twenty-four rabbits were systemically anesthetized, and the stromata of their right corneas were inoculated with Fusarium solani [105 colony-forming units (CFU) per milliliter]. Rabbits were divided into 2 groups: one was treated with CXL 72 hours after infection and the other did not receive any treatment (control). All eyes in both the groups were examined before (days 0 and 3) and after (day 7) CXL treatment. The eyes were enucleated, and corneal buttons were sent for microbiological and histological examinations.

Results: All animals developed Fusarium keratitis; there was no statistically significant difference between groups before treatment (day 0, P = 0.397 and day 3, P = 0.702). After CXL treatment, the difference in clinical scores on day 7 between groups was statistically significant (P = 0.00); the CXL group showed significant lower clinical score. The CXL group had 22.45 ± 5.09 CFU/g compared with 42.5 ± 3.12 CFU/g in the control group; this difference was statistically significant (P = 0.01). In the 3 buttons of the control group, similar amounts of Fusarium hyphae and inflammatory cells were observed. In 2 of the 3 buttons analyzed from the CXL group, fewer Fusarium hyphae, inflammatory cells, and nonspecific stromal changes were observed compared with the control group.

Conclusions: Treatment of fungal keratitis with CXL seems to be effective in decreasing the intensity and severity of infectious keratitis by F. solani. This therapy may be useful as a coadjuvant in the medical treatment of resistant infections.

Author Information

From the *Laboratorio de Investigaciones Oculares, Buenos Aires, Argentina; †Hospital Pedro Lagleyze, Buenos Aires, Argentina; and ‡BioFundus, Buenos Aires, Argentina.

Received for publication July 13, 2010; revision received February 6, 2011; accepted April 25, 2011.

The authors state that they have no financial or conflicts of interest to disclose.

Reprints: Martín Berra, Laboratorio de Investigaciones Oculares, Departamento de Patología, Facultad de Medicina, Universidad de Buenos Aires, José E. Uriburu 950, entrepiso, 1114 Buenos Aires, Argentina (e-mail: martinberra81@hotmail.com).

© 2012 Lippincott Williams & Wilkins, Inc.